Recent research have focused on the convergence of GLP-1|GIP|GCGR stimulant therapies and dopaminergic communication. While GCGR stimulators are commonly employed for managing type 2 diabetes mellitus, their emerging impacts on reinforcement circuits, specifically governed by dopamine networks, are gaining considerable attention. This report detail